Clinical trial NCT00797953: Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina
Official title: A Phase II, Double Blind, Placebo-controlled, Randominzed, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of T89 in Patient With Chronic Stable Angina Pectoris
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Angina Pectoris
Keywords: Angina Pectoris Treatment
Lead sponsor: Tasly Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2008-11-25
Enrollment: 124
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the anti-angina effect and dose response of T89, a 2-herb botanical drug product, in patients with chronic stable angina pectoris in the United States.

Detailed description: T89 is a modernized and industrialized version of a traditional Chinese herbal medicine. T89 was approved for marketing as a drug, for the treatment of chronic stable angina pectoris due to coronary heart disease, by the State Food and Drug Administration (SFDA) of China in 1993. There were more than 2 billion doses have been prescribed or used, in about 10,000,000 subjects, in short or long-term administration worldwide.

The product is also marketed, as a drug, in Russia, South Korea, Mongolia, Singapore, Vietnam, and South Africa. The current study is to determine the anti-angina effect and dose response of T89 in patients with chronic stable angina pectoris in the United States.

T89 consists of Danshen (Radix Salviae Miltiorrhizae, RSM) and Sanqi (Radix Notoginseng, RN) as active constitutes, and using Borneol as transporting enhancer.

Eligibility criteria: Inclusion Criteria:

1. Patient must be between the ages of 18 and 80 years.
2. Females of childbearing potential must have a negative pregnancy test, not be breast feeding and established on a method of contraception that in the investigator's opinion is acceptable. Females must agree to remain on their established method of contraception through their participation in the study.
3. Evidence of coronary artery disease that consists of a well-documented medical history (over 3 months prior to the enrollment) of myocardial infarction or significant coronary artery disease with noninvasive or angiographic confirmation.
4. Symptoms that support the diagnosis of chronic angina and/or a history of an abnormal exercise response limited by angina and/or electrocardiograph (ECG) changes.
5. Moderate angina pectoris (Class II or Class III, Grading of Angina Pectoris by the Canadian Cardiovascular Society Classification System)
6. Naive patient or patient who's Total Exercise Duration (TED) is between 3 to 7 minutes in ETT on Standard Bruce Protocol, and the difference in TED must be no more than 15% between the two screen examinations on day -7 and day 0
7. All anti-angina regimen (except short-acting nitroglycerin, and one beta-blocker or calcium channel blocker), warfarin or other oral anticoagulants which were used prior to this initial visit can be discontinued.
8. Patient must understand and be willing, able and likely to comply with all study procedures and restrictions and comprehends the verbal rating scales and diary cards.
9. Patient must be able to give voluntary written informed consent.

Exclusion Criteria:

1. With contraindication to perform treadmill Exercise Tolerance Test (ETT).
2. Pre-exercise ST-segment depression of at least 1 mm in any lead, left bundle branch block, digoxin therapy, Left Ventricular Hypertrophy (LVH) and Wolff-Parkinson-White (WPW) syndrome or other factors that could interfere with exercise electrocardiograph interpretation.
3. Clinically significant arrhythmias or atrioventricular conduction block greater than first degree.
4. Clinically significant co-morbidities, including hepatic or renal dysfunction, pulmonary hypertension, chronic obstructive pulmonary disease, history of cerebral hemorrhage, or seizure disorders that required anticonvulsant medication.
5. History of congestive heart failure, unstable angina, severe valvular disease, severe hypertension, severe anemia, suspected or known dissecting aneurysm, acute myocarditis or pericarditis, thrombophlebitis or pulmonary embolism or recent myocardial infarction within three months of study entry.
6. History of bleeding diathesis, or is on warfarin.
7. Implanted pacemaker.
8. Aspirin and/or statins started less than 14 days prior to the signing of informed consent.
9. Pregnancy or lactation.
10. Inability to discontinue existing chronic nitrate regimen (e.g. long acting nitroglycerin) and allow only short-acting nitroglycerin and one beta-blocker or calcium channel blocker.
11. Clinical trials/experimental medication:

    * Participation in any other clinical trial or receipt of an investigational drug within 90 days prior to initial visit.
    * Those patients unable, in the opinion of the investigator, to comply fully with the trial requirements.
    * Previous participation in this study.
12. Substance abuse. Patients with a recent history (within the last 2 years) of alcoholism or known drug dependence.
13. Patient is a family member or relative of the study site staff.

Primary outcomes:
measure: Total Exercise Duration (TED) change from screen baseline value in Exercise Tolerance Test (ETT) on Standard Bruce Protocol at trough drug levels at the end of the 4th and 8th week of treatment compared to placebo.
timeFrame: 12 weeks
Secondary outcomes:
measure: Frequency of weekly angina episodes
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Paradigm Clinical, Inc.
state: Arizona
city: Beverly Hills
country: United States
facility: Robert M. Karns, A Medical Corporation
state: California
city: Corona
country: United States
facility: Inland Heart Doctors
state: California
city: Lauderdale Lakes
country: United States
facility: Sunrise Medical Research
state: Florida
city: Miami
country: United States
facility: Cardiovascular Research Center of South Florida
state: Florida
city: Alexandria
country: United States
facility: Alexandria Cardiology Clinic
state: Louisiana
city: Bay City
country: United States
facility: Great Lakes Research Group, Inc
state: Michigan
city: Williamsville
country: United States
facility: Marc Kozinn Associates
state: New York
city: Oklahoma
country: United States
facility: Oklahoma Cardiovascular & Hypertension
state: Oklahoma
city: Columbia
country: United States
facility: Three Rivers Medical Associates
state: South Carolina
city: Houston
country: United States
facility: East Texas Cardiology
state: Texas
city: Houston
country: United States
facility: Northwest Houston Cardiology
state: Texas
city: Tomball
country: United States
facility: Northwest Heart Center
state: Texas
city: Norfolk
country: United States
facility: National Clinical Research-Norfolk, Inc
state: Virginia
city: Madison
country: United States
facility: Gemini Scientific, LLC
state: Wisconsin
Study officials:
affiliation: Tasly Pharmaceuticals Co. Ltd.
name: Jason Zhixin Guo, MD
role: STUDY_DIRECTOR
References: